Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
NCT ID: NCT00044291
Last Updated: 2015-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
865 participants
INTERVENTIONAL
2002-06-30
2006-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
NCT00267553
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
NCT00097344
Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast Cancer
NCT00010322
Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer
NCT00004205
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
NCT00530868
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atamestane + toremifene
atamestane
toremifene
aromatase inhibition
hormone therapy
endocrine therapy
antiestrogen therapy
Letrozole + placebo
letrozole
aromatase inhibition
hormone therapy
endocrine therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
atamestane
toremifene
letrozole
aromatase inhibition
hormone therapy
endocrine therapy
antiestrogen therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pathological or histological confirmation of breast cancer at initial diagnosis or at the time of metastases
* ECOG performance status of 0, 1 or 2 or Karnofsky performance status of 60 or higher
* Predicted life expectancy of 12 weeks or more
* Postmenopausal endocrine status. LH/FSH levels in the postmenopausal range in women whose menopause occurred less than 5 years ago
* Locally recurrent, locally advanced, locally metastatic disease not amenable to radiation therapy or surgery and/or distant metastatic disease
* At least one tumor localization measurable in 2 dimensions (one diameter at least 2 cm for soft tissue/visceral disease assessed by CT/MRI scan or conventional X-ray technique, one diameter at least 1 cm for bone lesions assessed by conventional X-ray techniques)
* Estrogen receptor and/or progesterone receptor positive (by laboratory/institutional standard) at the time of initial diagnosis or determined during subsequent biopsy/surgery of metastases
* Written informed consent obtained
Exclusion Criteria
* Prior adjuvant therapy with aromatase inhibitors or antiestrogens/SERMs within 12 months prior to enrollment
* Progression of disease during therapy with antiestrogens (including SERMs administered for prevention of osteoporosis)
* Life-threatening locally recurrent, locally advanced or metastatic disease or disease requiring chemotherapeutic intervention (such as inflammatory breast cancer)
* History of known CNS metastases, significant neurological dysfunction including active seizures, or clinical signs of other significant neurological diseases
* Other active malignancy (except basal cell carcinoma of the skin or in situ cervical cancer). Patients with previous malignancies must be without evidence of disease for at least five years
* Renal insufficiency (serum creatinine \> 2.0 mg/dL)
* Aspartate aminotransferase, alanine aminotransferase or serum bilirubin levels more than 2.5 times upper limit of normal
* Hemoglobin \<9 g/dL
* Platelet count of less than 100,000 platelets per mm3
* Total white blood cell count of less than 2,000 cells per mm3
* Premenopausal endocrine status; pregnant or lactating females
* Usage of an investigational drug within the thirty (30) days prior to enrollment; or the planned usage of an investigational drug other than the study medication during the course of the current study
* Contraindication to use of toremifene, atamestane, letrozole or any of the inactive components of their formulations
* Prior enrollment in this study
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Intarcia Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Paul Goss, M.D.
Role: STUDY_CHAIR
Princess Margaret Hospital, Canada
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Midwest Internal Medicine, PLLC
Lake Havasu City, Arizona, United States
Arizona Clinical Research Center
Tucson, Arizona, United States
California Cancer Care, Inc.
Greenbrae, California, United States
Sharp Memorial Hospital
San Diego, California, United States
Innovative Medical Research of South Florida Inc.
Miami Shores, Florida, United States
Georgia Cancer Specialists
Tucker, Georgia, United States
Maryland Hematology/Oncology Associates
Baltimore, Maryland, United States
Oncology Care Associates, PLLC
Saint Joseph, Michigan, United States
Kansas City Oncology and Hematology Group
Kansas City, Missouri, United States
Great Falls Clinic-Oncology West
Great Falls, Montana, United States
Slocum-Dickson Medical Group
New Hartford, New York, United States
Hematology Oncology Consultants, Inc.
Columbus, Ohio, United States
Oncology Consultants
Houston, Texas, United States
First Dynamic Healthcare Services, Inc.
Killeen, Texas, United States
Cache Valley Cancer Treatment & Research Clinic
Logan, Utah, United States
Virginia Oncology Associates
Norfolk, Virginia, United States
Western Washington Oncology Inc., P.S.
Olympia, Washington, United States
Ottawa Regional Cancer Centre
Ottawa, Ontario, Canada
Northwestern Ontario Regional Cancer Centre
Thunder Bay, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
McGill University, Department of Oncology
Montreal, Quebec, Canada
Arkhangelsk Regional Oncology Center, Department of Chemotherapy
Arkhangelsk, , Russia
Tatarstan Republican Clinical Oncology Center
Kazan', , Russia
Krasnodar Regional Clinical Oncology Center, Chemotherapy Department
Krasnodar, , Russia
Lipetsk Regional Oncology Center, Department of General Oncology
Lipetsk, , Russia
Blokhin Cancer Research Center, Department of Chemotherapy and Combined Treatment of Tumors
Moscow, , Russia
Blokhin Cancer Research Center, Department of Chemotherapy
Moscow, , Russia
Blokhin Cancer Research Center, Department of Clinical Pharmacology and Chemotherapy
Moscow, , Russia
Blokhin Cancer Research Center, Department of New Antitumor Drug Research
Moscow, , Russia
Hertzen Research Institute of Oncology, Department of Chemotherapy
Moscow, , Russia
Central Clinical Hospital of the Ministry of Transport n.a. Semashko, Department of Chemotherapy
Moscow, , Russia
Moscow City Hospital #40, Department of Chemotherapy
Moscow, , Russia
Moscow City Oncology Hospital #62
Moscow, , Russia
Murmansk Regional Oncology Center
Murmansk, , Russia
Municipal Clinical Hospital #1, Department of Breast Tumors, Oncology Department
Novosibirsk, , Russia
Medical Radiological Research Center
Obninsk, , Russia
Ryazan Regional Clinical Oncology Center
Ryazan, , Russia
Leningrad Regional Oncology Center
Saint Petersburg, , Russia
St. Petersburg City Oncology Center
Saint Petersburg, , Russia
Laboratory of Thoracic Oncology, St. Petersburg Pavlov State Medical University, Research Institute of Pulmonology
Saint Petersburg, , Russia
Petrov Research Institute of Oncology, Department of Biotherapy and Bone Marrow Transplantation
Saint Petersburg, , Russia
Petrov Research Institute of Oncology, Department of Breast Cancer
Saint Petersburg, , Russia
Petrov Research Institute of Oncology, Department of Chemotherapy
Saint Petersburg, , Russia
Samara Regional Oncology Center, Department of Chemotherapy
Samara, , Russia
Stavropol Regional Oncology Center, Department of Chemotherapy
Stavropol, , Russia
Research Institute of Oncology, Tomsk Scientific Center, Siberian Department of the Russian Academy of Medical Sciences, Department of Chemotherapy
Tomsk, , Russia
V. Novgorod Regional Oncology Center, Department of Chemotherapy
V. Novgorod, , Russia
Burdenko Voronezh Medical Academy, Oncology Department, Clinical Facility: Regional Clinical Oncology Center
Voronezh, , Russia
Cherkassy Regional Oncology Center, Chemotherapy Department
Cherkassy, , Ukraine
Dnepropetrovsk State Medical Academy, Oncology Department. Clinical Facility: Dnepropetrovsk City Clinical Hospital #4
Dnipro, , Ukraine
Donetsk State Medical University. Clinical Facility: Donetsk Regional Antineoplastic Center, Mammology Department
Donetsk, , Ukraine
Ivano-Frankovsk State Medical Academy; Oncology Department Clinical Facility: Ivano-Frankovsk Regional Oncology Center
Ivano-Frankivsk, , Ukraine
Kharkov State Medical University. Clinical Facility: Grigoriev Medical Radiology Institute, Chemotherapy Department
Kharkiv, , Ukraine
Kharkov Medical Academy of Postgraduate Education, Oncology and Pediatric Oncology Department. Clinical Facility: Kharkov Regional Clinical Oncology Dispensary, Chemotherapy Department
Kharkiv, , Ukraine
Kiev Central Clinical Hospital, Ukraine Security Services, Surgery Department
Kiev, , Ukraine
Kiev Oncology Institute, Ukraine Medical Science Academy, Department of Breast Tumors
Kiev, , Ukraine
Kiev Postgraduate Studies Medical Academy. Clinical Facility: Kiev City Oncology Hospital, Chemotherapy Department
Kiev, , Ukraine
National Medical University, Oncology Department. Clinical Facility: Kiev City Oncology Hospital, Surgery Department
Kiev, , Ukraine
Krivoy Rog City Oncology Center
Kryvyi Rih, , Ukraine
Lviv State Medical University, Oncology and Medical Radiology Department. Clinical Facility: Lviv State Oncology Regional Clinical Diagnostic Center, Chemotherapy Department
Lviv, , Ukraine
Odessa State Medical University, Oncology Department. Clinical Facility: Odessa Regional Oncology Center, Chemotherapy Department
Odesa, , Ukraine
Uzhgorod National University Oncology Course of Surgery Department of Postgraduate Education Faculty Clinical Facility: Zakarpatye Regional Oncology Center
Uzhhorod, , Ukraine
Zaporozhye Statue Institute of Postgraduate Training. Oncology Department; Clinical Facility: Zaporozhye Regional Oncology Center
Zaporizhzhya, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Biomed 777-CLP-29
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.